Allergy Therapeutics (AGY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Allergy Therapeutics (AGY) has a cash flow conversion efficiency ratio of 0.748x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-21.09 Million ≈ $-2.57K USD) by net assets (GBX-28.19 Million ≈ $-3.43K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AGY equity financing ratio to measure how much of total assets are equity-financed.
Allergy Therapeutics - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Allergy Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Allergy Therapeutics (AGY) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Allergy Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allergy Therapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enrg Elements Ltd
AU:EEL
|
-0.578x |
|
Visionstate Corp
V:VIS
|
0.511x |
|
Banzai International Inc
NASDAQ:BNZI
|
-0.679x |
|
YouGov plc
LSE:YOU
|
0.045x |
|
AS Rigas kugu buvetava
STU:UW3
|
-0.045x |
|
Yu Group PLC
LSE:YU
|
0.203x |
|
Lifeclean International AB
ST:LCLEAN
|
-1.045x |
|
LM Funding America Inc
NASDAQ:LMFA
|
-0.181x |
Annual Cash Flow Conversion Efficiency for Allergy Therapeutics (2002–2025)
The table below shows the annual cash flow conversion efficiency of Allergy Therapeutics from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see Allergy Therapeutics (AGY) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX-28.19 Million ≈ $-3.43K |
GBX-28.72 Million ≈ $-3.49K |
1.019x | +111.76% |
| 2024-06-30 | GBX3.71 Million ≈ $451.28 |
GBX-32.14 Million ≈ $-3.91K |
-8.665x | +42.10% |
| 2023-06-30 | GBX2.07 Million ≈ $251.37 |
GBX-30.92 Million ≈ $-3.76K |
-14.964x | -3904.84% |
| 2022-06-30 | GBX37.77 Million ≈ $4.59K |
GBX-14.11 Million ≈ $-1.72K |
-0.374x | -312.95% |
| 2021-06-30 | GBX48.53 Million ≈ $5.91K |
GBX8.52 Million ≈ $1.04K |
0.175x | -37.42% |
| 2020-06-30 | GBX43.78 Million ≈ $5.33K |
GBX12.28 Million ≈ $1.49K |
0.280x | +88.05% |
| 2019-06-30 | GBX37.56 Million ≈ $4.57K |
GBX5.60 Million ≈ $681.36 |
0.149x | +190.33% |
| 2018-06-30 | GBX23.03 Million ≈ $2.80K |
GBX-3.80 Million ≈ $-462.59 |
-0.165x | -2878.67% |
| 2017-06-30 | GBX29.96 Million ≈ $3.65K |
GBX178.00K ≈ $21.66 |
0.006x | +101.52% |
| 2016-06-30 | GBX30.32 Million ≈ $3.69K |
GBX-11.84 Million ≈ $-1.44K |
-0.390x | -530.91% |
| 2015-06-30 | GBX34.47 Million ≈ $4.19K |
GBX3.12 Million ≈ $379.98 |
0.091x | -37.14% |
| 2014-06-30 | GBX15.07 Million ≈ $1.83K |
GBX2.17 Million ≈ $264.39 |
0.144x | -13.04% |
| 2013-06-30 | GBX14.67 Million ≈ $1.79K |
GBX2.43 Million ≈ $295.90 |
0.166x | -16.01% |
| 2012-06-30 | GBX14.59 Million ≈ $1.78K |
GBX2.88 Million ≈ $350.41 |
0.197x | +120.83% |
| 2011-06-30 | GBX2.14 Million ≈ $260.25 |
GBX-2.03 Million ≈ $-246.63 |
-0.948x | -316.36% |
| 2010-06-30 | GBX3.89 Million ≈ $472.81 |
GBX1.70 Million ≈ $207.08 |
0.438x | +2206.97% |
| 2009-06-30 | GBX-23.18 Million ≈ $-2.82K |
GBX-440.00K ≈ $-53.54 |
0.019x | -98.89% |
| 2008-06-30 | GBX-11.29 Million ≈ $-1.37K |
GBX-19.32 Million ≈ $-2.35K |
1.711x | +177.93% |
| 2007-06-30 | GBX8.60 Million ≈ $1.05K |
GBX-18.88 Million ≈ $-2.30K |
-2.196x | -786.27% |
| 2006-06-30 | GBX32.70 Million ≈ $3.98K |
GBX-8.10 Million ≈ $-985.90 |
-0.248x | -8630.66% |
| 2005-06-30 | GBX20.08 Million ≈ $2.44K |
GBX-57.00K ≈ $-6.94 |
-0.003x | -101.05% |
| 2004-06-30 | GBX7.08 Million ≈ $860.94 |
GBX1.91 Million ≈ $231.91 |
0.269x | -28.68% |
| 2003-06-30 | GBX5.55 Million ≈ $674.91 |
GBX2.10 Million ≈ $254.90 |
0.378x | -17.28% |
| 2002-06-30 | GBX-4.40 Million ≈ $-535.11 |
GBX-2.01 Million ≈ $-244.32 |
0.457x | -- |
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more